Navigation Links
Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene

Pursing International Market Opportunities for the Company's Medical


ANNAPOLIS, Md., Aug. 11 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that Lord Lewis Moonie has joined the Company as a special UK government advisor.

Lord Moonie will assist PharmAthene in exploring interest and support for the Company's biodefense programs and product candidates within the UK government.

"We are honored to welcome Lord Moonie to PharmAthene in this advisory capacity and are delighted to have the opportunity to leverage his significant knowledge of the UK biodefense industry and amongst our NATO allies," stated David P. Wright, President and Chief Executive Officer of PharmAthene. "Lord Moonie's medical background and extensive experience as a Member of Parliament, as well as his oversight of the Research Establishment at Porton Down, which included recombinant vaccines for plague and anthrax, will be invaluable to us as we continue to expand awareness and the market for our biodefense countermeasures among our Allies. We view Lord Moonie's appointment as an important step in the execution of our international strategy to meet the urgent needs of nations internationally requiring medical countermeasures."

Lord Moonie retired from the UK's House of Common in 2005 after eighteen years as Member of Parliament for Kirkcaldy. During this time, Lord Moonie spent three and a half years as a junior minister in the Ministry of Defence (MOD), with responsibility for all of MOD's Science and Technology, including the Defence Diversification Agency. Prior to this he was a consultant in public health medicine in the NHS. Following his service in the MOD, Lord Moonie was chairman of a pre-legislative committee of both the House of Commons and House of Lords which scrutinized the draft Civil Contingencies Bill.

Since 2004, Lord Moonie has served as a non-executive director of AEA Technology, which provides a wide range of consultancy and advisory services, and program management to government in the fields of energy management and the environment.

Lord Moonie is a member of the Board of Trustees of the charity Skillforce, and is a consultant in a variety of fields, including energy, health services and communications. He currently sits on the European Advisory Board of Northrop Grumman and is a non-executive director of Party Gaming.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine

-- Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection

-- Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

-- RypVax(TM) -- a recombinant dual antigen vaccine for plague a third generation rPA anthrax vaccine.

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's public disclosure filings with the U.S. Securities and Exchange Commission (the "SEC"). Furthermore, there can be no assurance that our engagement of Lord Moonie will result in the award of any contracts with the UK government or any ministries, departments, agencies and the like thereof to PharmAthene. Copies of PharmAthene's public disclosure filings are available from its investor relations department.

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biovail Concerned Shareholders Welcome Glass Lewis Evaluation
2. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
3. Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Boards Directors
4. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
5. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
6. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
7. Serving Those Who Serve Our Country: Medical Device Company Answers the Call of a U.S. Combat Hospital in Iraq
8. Group Hotel Rate Ends Friday: Reserve Now for Leadership Development Conference June 4-6
9. MedThink Hires Two Executives to Serve its Growing Pharmaceutical Client Base
10. Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University
11. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Post Your Comments:
(Date:11/28/2015)... ... , ... • Jeon Jin Bio Corp, a Korean Biotech venture company, has ... , Bird Free, an oil-based, gel formula made from ... visual, smell, taste and touch, enabling safe, effective avian control without toxic chemicals , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
(Date:10/26/2015)... , October 26, 2015 ... --> adds Biometrics Market ... 2021 as well as Emerging Biometrics ... reports to its collection of IT ... . --> ...
Breaking Biology News(10 mins):